Novel Diagnostic, Mechanistic and Treatment Approaches for Effective Management of Neuronal Injuries

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 6709

Special Issue Editor


E-Mail Website
Guest Editor
Bioengineering and Regenerative Medicine, Department of Biomedical Engineering, University of Basel/University Hospital, Basel, Switzerland
Interests: bioengineering; stem cells; biomaterials; drug delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Injuries to the nervous system often result in debilitating functional impairment and reduced quality of life which are all associated with huge socio-economic impact. Currently existing diagnostic and therapeutic options are sub-optimal. Thus, there is great need for new and innovative strategies for effective management of differential pathologies resulting from various forms of neuronal injuries. The current special issue invites research articles for the following topics.

  • Engineered biomaterials, bioengineered cells and tissues
  • Nanomedicine and targeted drug delivery
  • Multiomics covering the proteomic, genomic and transcriptomics of tissues with changing functions and anatomy. 
  • Bioelectronics as a potential therapeutic intervention
  • Cellular and molecular neurobiology
  • Pre-clinical, clinical and surgical approaches for regeneration of peripheral and central nervous system

Dr. Srinivas Madduri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 3426 KiB  
Article
Optimized Decellularization Protocol for Large Peripheral Nerve Segments: Towards Personalized Nerve Bioengineering
by Alois Hopf, Lina Al-Bayati, Dirk J. Schaefer, Daniel F. Kalbermatten, Raphael Guzman and Srinivas Madduri
Bioengineering 2022, 9(9), 412; https://doi.org/10.3390/bioengineering9090412 - 24 Aug 2022
Cited by 3 | Viewed by 2966
Abstract
Nerve injuries remain clinically challenging, and allografts showed great promise. Decellularized nerve allografts possess excellent biocompatibility and biological activity. However, the vast majority of decellularization protocols were established for small-size rodent nerves and are not suitable for clinical application. We aimed at developing [...] Read more.
Nerve injuries remain clinically challenging, and allografts showed great promise. Decellularized nerve allografts possess excellent biocompatibility and biological activity. However, the vast majority of decellularization protocols were established for small-size rodent nerves and are not suitable for clinical application. We aimed at developing a new method of decellularizing large-diameter nerves suitable for human transplantation. Repeated rounds of optimization to remove immunogenic material and preserve the extracellular structure were applied to the porcine sciatic nerve. Following optimization, extensive in vitro analysis of the acellular grafts via immunocytochemistry, immunohistology, proteomics and cell transplantation studies were performed. Large segments (up to 8 cm) of the porcine sciatic nerve were efficiently decellularized and histology, microscopy and proteomics analysis showed sufficient preservation of the extracellular matrix, with simultaneous consistent removal of immunogenic material such as myelin, DNA and axons, and axonal growth inhibitory molecules. Cell studies also demonstrated the suitability of these acellular grafts for 3D cell culture studies and translation to future large animal studies and clinical trials. By using non-human donors for peripheral nerve transplantation, significant drawbacks associated with the gold standard can be eliminated while simultaneously preserving the beneficial features of the extracellular matrix. Full article
Show Figures

Figure 1

Review

Jump to: Research

12 pages, 840 KiB  
Review
Application of Sygen® in Diabetic Peripheral Neuropathies—A Review of Biological Interactions
by Marcelo Amaral Coelho, Madhan Jeyaraman, Naveen Jeyaraman, Ramya Lakshmi Rajendran, André Atsushi Sugano, Tomas Mosaner, Gabriel Silva Santos, João Vitor Bizinotto Lana, Anna Vitória Santos Duarte Lana, Lucas Furtado da Fonseca, Rafael Barnabé Domingues, Prakash Gangadaran, Byeong-Cheol Ahn and José Fábio Santos Duarte Lana
Bioengineering 2022, 9(5), 217; https://doi.org/10.3390/bioengineering9050217 - 18 May 2022
Cited by 2 | Viewed by 3213
Abstract
This study investigates the role of Sygen® in diabetic peripheral neuropathy, a severe disease that affects the peripheral nervous system in diabetic individuals. This disorder often impacts the lower limbs, causing significant discomfort and, if left untreated, progresses into more serious conditions [...] Read more.
This study investigates the role of Sygen® in diabetic peripheral neuropathy, a severe disease that affects the peripheral nervous system in diabetic individuals. This disorder often impacts the lower limbs, causing significant discomfort and, if left untreated, progresses into more serious conditions involving chronic ulcers and even amputation in many cases. Although there are management strategies available, peripheral neuropathies are difficult to treat as they often present multiple causes, especially due to metabolic dysfunction in diabetic individuals. Gangliosides, however, have long been studied and appreciated for their role in neurological diseases. The monosialotetrahexosylganglioside (GM1) ganglioside, popularly known as Sygen, provides beneficial effects such as enhanced neuritic sprouting, neurotrophism, neuroprotection, anti-apoptosis, and anti-excitotoxic activity, being particularly useful in the treatment of neurological complications that arise from diabetes. This product mimics the roles displayed by neurotrophins, improving neuronal function and immunomodulation by attenuating exacerbated inflammation in neurons. Furthermore, Sygen assists in axonal stabilization and keeps nodal and paranodal regions of myelin fibers organized. This maintains an adequate propagation of action potentials and restores standard peripheral nerve function. Given the multifactorial nature of this complicated disorder, medical practitioners must carefully screen the patient to avoid confusion and misdiagnosis. There are several studies analyzing the role of Sygen in neurological disorders. However, the medical literature still needs more robust investigations such as randomized clinical trials regarding the administration of this compound for diabetic peripheral neuropathies, specifically. Full article
Show Figures

Figure 1

Back to TopTop